close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Merus N.V.

< Previous 1 2 Next >
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Present at the 2025 Wells Fargo Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus N.V. Announces Pricing of Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus N.V. Announces Proposed Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Present at BofA Securities 2025 Health Care Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire
Tickers BHVN MRUS
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Receives FDA extension of PDUFA for zenocutuzumab
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today